ArticleAmerican journal of epidemiology2008
Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?
Article in American journal of epidemiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.International journal of cancer · 2013Pooled it
- Human Papilloma Virus Persistence after Cone Excision in Women with Cervical High Grade Squamous Intraepithelial Lesion: A Prospective Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2016Article
- Discrete-time semi-Markov modeling of human papillomavirus persistence.Statistics in medicine · 2011Article
- Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Article
- Human papillomavirus persistence in young unscreened women, a prospective cohort study.PloS one · 2011Article
- Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.Journal of the National Cancer Institute · 2010Article
- Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.Journal of clinical microbiology · 2009Article
- Human papillomavirus genotyping using an automated film-based chip array.The Journal of molecular diagnostics : JMD · 2009Article
- The impact of human papillomavirus vaccination on cervical cancer prevention efforts.Gynecologic oncology · 2009Review
- Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.BMJ (Clinical research ed.) · 2009Article
- Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting.Obstetrics and gynecology · 2009Article
- Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.Journal of clinical microbiology · 2009Article
- Comparison of two PCR-based human papillomavirus genotyping methods.Journal of clinical microbiology · 2008Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent cervical infections by approximately 15 carcinogenic genotypes of human papillomavirus (HPV) cause virtually all cases of cervical cancer and its immediate precancerous precursor, cervical intraepithelial neoplasia grade 3 or carcinoma in situ. As is shown in a meta-analysis by Koshiol et al. (Am J Epidemiol 2008;168:123-137), detection of carcinogenic HPV viral persistence could be used to identify women at the greatest risk of cervical precancer. Specifically, women who have carcinogenic HPV infection that persists for at least 1 year versus those whose infections clear are at significantly elevated risk of having or developing cervical precancer. However, before detection of HPV persistence can be used in cervical cancer screening, several considerations need to be addressed: 1) validation and Food and Drug Administration approval of a reliable HPV genotyping test, 2) rational clinical algorithms based on risk of precancer and cancer for the clinical management of HPV persistence, 3) clinician and patient acceptability of monitoring of HPV infections (including not responding excessively to the first positive HPV test and waiting 1-2 years for infections to either persist or resolve), and 4) patient compliance with recommended follow-up. Investigators will need to address these and other key issues in order to realize the potential utility of HPV viral monitoring for improving the accuracy of cervical cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.